Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

Trial Profile

Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Imatinib (Primary) ; Dihydroartemisinin/piperaquine
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Fibroma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Mesothelioma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Systemic mastocytosis
  • Focus Pharmacodynamics
  • Acronyms MIM
  • Most Recent Events

    • 27 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 27 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
    • 27 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top